过敏性鼻炎口服液对常年性变态反应性鼻炎S-IgE及IL-4的影响  

Influence of Allergic Rhinitis Oral Liquid on S-IgE and IL-4 in Perennial Allergic

作　　者：冯纬纭[1] 张勉[1] 方燕飞[1] 韦子章[1] 黄卓燕[1] 

机构地区：[1]广西中医学院第一附属医院,广西南宁530023

出　　处：《时珍国医国药》2005年第12期1232-1234,共3页Lishizhen Medicine and Materia Medica Research

基　　金：广西青科学基金资助项目(No.0135015)

摘　　要：目的:探讨过敏性鼻炎口服液治疗常年性变态反应性鼻炎对S-IgE及IL-4的影响。方法:将符合常年性变态反应性鼻炎诊断标准且符合纳入标准的129例患者随机分配到过敏性鼻炎口服液组(A组),鼻炎康组(B组),安慰组(C组),观察他们白细胞介素4(IL-4)血清特异性IgE(S-IgE)的变化情况。结果:三组的总有效率分别为93.02%,65.12%,6.98%。A,B组疗效均优于C组(P<0.01);PAR患者治疗前的IL-4、S-IgE水平与健康组比较均有非常显著性差异(P<0.01);治疗后A,B组的IL-4均明显低于治疗前(P<0.05),A组的S-IgE明显低于治疗前(P<0.05);治疗前后IL-4的差值三组两两比较均有显著性差异(P<0.05),治疗前后S-IgE的差值两两比较A与B有显著性差异(P<0.05),A与C有非常显著性差异(P<0.01)。结论:PAR患者的IL-4、S-IgE水平明显高于健康组;A,B组对PAR均有治疗作用,但A组优于B组;A,B组均能降低PAR患者的IL-4水平,但A组优于B组;A组能降低PAR患者的S-IgE水平;过敏性鼻炎口服液通过同时降低PAR患者的IL-4、S-IgE水平而有效地治疗PAR。Objective To study the mechanism of the treatment of perennial allergic rhinitis （RAP） with Allergic Rhinitis Oral Liquid （AROL）. Methods 69 cases, who were diagnosed as PAR and met the accepted standard for this present study, were randomly divided into AROL group （ A group ）, Bi Yan Kang group （ B group ）, Placebo （ C group）, as well as healthy group （ D group） as controlled group. The change of onterleukin -4 （ IL-4 ） and serum specific IgE （ S-IgE ） were observed before and after imposed different factors. Results The total effective rates of the three treating groups were respectively 93.2% , 65. 12% and 6.98%. The therapeutic effects of A and B groups were better than C group （P〈0.01 ） ; In PAR groups,comparing PAR groups with the healthy group, IL-4 and S-IgE markedly increased before processing （P〈 0.01 ） ;After processing, the IL-4 markedly decreased in A and B groups （P〈0.05）, S-IgE markedly decreased in A group （P〈0.05 ） ; There were significant differences in the deviation value among the A, B and C groups after processing （P 〈 0.05）. There was a significant difference in S-IgE between A and B groups （ P 〈 0.05）. There was a very significant difference in S-IgE between A and C group （P〈0.01）. Conclusion 1. The level of IL-4 and S-IgE in PAR was higher than healthy group. 2. Treatments in A and B group were effective on PAR, and treatment in A group was better than B group. 3. Treatments in A and B group could reduce the level of IL-4, and treatment in A group was better than B group. 4. Treatment in A group could reduce S-IgE in PAR patients. 5. AROL is effective in the treatment of PAR through reducing the levels of both IL-4 and S-IgE.

关 键 词：常年性变态反应性鼻炎 过敏性鼻炎口服液 白细胞介素4 血清特异性IGE 

分 类 号：R285.6[医药卫生—中药学]